5901 Indian School Rd. NE
Albuquerque, NM 87110
With 1.4 billion people, China is the world’s second largest drug market, soon to be #1. CFDA policies now allow for in-country contract manufacturing and expanded access to modern drugs, an unprecedented opportunity for multi-national biopharm companies (MNCs). PaizaBio assists MNCs seeking a fast-track manufacturing presence in China’s sterile injectable drug sector. Located in Hangzhou, PaizaBio's contract manufacturing/fill-and-finish operation has an annual capacity of 400 million units annually (small molecule) and adheres to western cGMP quality standards and manufacturing practices. PaizaBio's state-of-the-art operations include ten high-speed automated filling lines, advanced lyophilization, packaging, laboratory testing, validation, analysis, and development; and climate controlled warehouse. We also offers CFDA regulatory support and consulting along with the Trans-Pacific Aseptic Institute of Training (TPAIT), which provides world-class training in aseptic processing.